Immunic, Inc.

What they do

Immunic is headquartered in New York City with research and development operations in Grafelfing near Munich, Germany, and had approximately 100 employees as of July 31, 2026. The company develops orally administered small molecule programs for neurologic and autoimmune diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in Phase 3 development for relapsing MS, with an additional Phase 3 trial in progressive MS planned. Earlier-stage programs include IMU-381 and IMU-856.

Revenue drivers

• Vidofludimus calcium (IMU-838) in relapsing MS — Lead asset in the Phase 3 ENSURE program; the company is building commercial, regulatory and organizational capabilities for a potential launch in relapsing MS. No product revenue has been reported.
• Vidofludimus calcium in progressive MS — A confirmatory Phase 3 program in progressive MS is planned to be initiated later in 2026, extending the same asset into a second MS population.
• Earlier-stage pipeline (IMU-381 and IMU-856) — Preclinical/earlier-stage oral small molecules intended to build a broader therapeutics platform in neurodegenerative and autoimmune diseases; no revenue contribution disclosed.

Recent performance

Immunic has reported no product revenue and has recorded annual net losses of $92.9M (2021), $120.4M (2022), $93.6M (2023), $100.5M (2024) and $97.2M (2025). Operating cash flow has been negative each year, at $83.2M, $65.1M, $70.8M, $84.8M and $85.8M used in 2021 through 2025, respectively. Diluted EPS improved from -$3.93 in 2021 to -$0.62 in 2025. As of June 30, 2026, the company reported total assets of $159.2M, total liabilities of $31.6M, shareholder equity of $127.6M and cash and equivalents of $155.1M. Dividends per share were $0 in each year from 2021 through 2025.

Strategy

The company states it is focused on development and potential commercialization of orally administered small molecule programs addressing unmet needs in neurologic and autoimmune diseases. It says vidofludimus calcium positions it to pivot toward becoming a fully integrated commercial-stage MS company, and it is building commercial, regulatory and organizational capabilities to support a potential launch in relapsing MS while advancing the pipeline in progressive MS. In April 2026, stockholders approved and the company effected a 1-for-10 reverse stock split effective April 27, 2026. The board was expanded with the appointment of Elena Ridloff, CFA, effective August 6, 2026, citing financial, capital markets and commercial experience as the company approaches the Phase 3 ENSURE readout.

Risks

• No product revenue — Immunic has recorded no product revenue in the reported periods and has relied on losses and negative operating cash flow, including $85.8M of operating cash used in 2025.
• Clinical and regulatory risk on vidofludimus calcium — The company's prospects hinge on the Phase 3 ENSURE program in relapsing MS, with top-line data expected by year-end 2026, and on a planned confirmatory Phase 3 program in progressive MS.
• Capital sufficiency — The company makes forward-looking statements regarding the sufficiency of its capital resources to fund operations, and it had $155.1M of cash and equivalents at June 30, 2026.
• Organizational and governance changes — The company has reported multiple director or officer changes since mid-2026, including board appointments, as it prepares for potential regulatory filings and commercialization.

Outlook

Management states that top-line data from the Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS are expected by year-end 2026. The company also states that initiation of an additional Phase 3 clinical trial in progressive MS is expected later in 2026. Immunic says it is building the commercial, regulatory and organizational capabilities to support a potential launch in relapsing MS.